(Q38795784)

6 September 2017

Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer (English)

1 reference

6 September 2017

0 references

1 reference

1 reference

V Michalaki

1

1 reference

6 September 2017

K Syrigos

series ordinal

2

1 reference

6 September 2017

P Charles

series ordinal

3

1 reference

6 September 2017

J Waxman

series ordinal

4

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

British Journal of Cancer

6 September 2017

1 reference

6 September 2017

90

1 reference

6 September 2017

12

1 reference

6 September 2017

2312-2316

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601814

6 September 2017

0 references

cites work

Bloodborne biomolecular markers in prostate cancer development and progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Interleukin-6 and prostate cancer progression

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway .

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Interleukin-6: a candidate mediator of human prostate cancer morbidity

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor"

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409519

Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells

1 October 2018

1 reference

12 December 2020

Serum interleukin 6 as a prognostic factor in patients with prostate cancer

1 reference

12 December 2020

Cytokine variations in patients with hormone treated prostate cancer

1 reference

12 December 2020

Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis

1 reference

12 December 2020

Longitudinal screening for prostate cancer with prostate-specific antigen

1 reference

12 December 2020

Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer

1 reference

12 December 2020

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

1 reference

12 December 2020

Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer

1 reference

12 December 2020

Dimensions Publication ID

Identifiers

DOI

10.1038/SJ.BJC.6601814

0 references

0 references

1 reference

6 September 2017

1 reference